FDA Approves Keytruda for Heavily Treated Classical Hodgkin’s Lymphoma Patients
News
The anti-PD-1 immunotherapy Keytruda (pembrolizumab) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults and children with refractory classical Hodgkin’s lymphoma (cHL) who have ... Read more